The FDA has accepted Merck's application for approval for its blood clot drug vorapaxar. The anticoagulant medication is meant to prevent stroke and myocardial infarction in patients who have experienced MI but not stroke. The therapy had been seen as a possible blockbuster, but safety concerns led Merck to narrow the indications.

Related Summaries